µå·°ÀÎÆ÷¸¦ ½ÃÀÛÆäÀÌÁö·Î ·Î±×ÀΠȸ¿ø°¡ÀÔ »çÀÌÆ®¸Ê
logo
  ½ÅÅëÇÕ°Ë»ö icon  
  ¾ÆÀÌÄܾàǰ°Ë»ö|ÀÓºÎÅõ¿©|ATCºÐ·ùÄÚµå|ÀûÀÀÁõ|ÇѹæÃÊÀç»çÁø|¼öÀ¯µî±Þ
left1
 ¾àǰ°Ë»ö  Á¦Ç°½Äº°  »óÈ£ÀÛ¿ë  ¼ººÐÁ¤º¸  È¯ÀÚº¹¾àÁöµµ  ¾àÁ¦ºñ½É»çÁöħ  µå·¯±×ÀÎÆ÷¸ô  °Ô½ÃÆÇ  Ä¿¹Â´ÏƼ  
right1
left2
 
right2
 
top
¾ÆÀ̵ðÀúÀå º¸¾ÈÁ¢¼Ó
line
ȸ¿ø°¡ÀÔ ¾ÆÀ̵ðºñ¹Ð¹øÈ£Ã£±â
·Î±ä¹®Á¦
bottom
ÀǾàÀü¹®°Ô½ÃÆÇ
ÀǾàǰQ&A
ÀǾà°Ç°­´º½º
Ãֽž๰Á¤º¸
ÀÚ·á½Ç
bottom
 

 
 
 
   
icon1 icon2 ÀǾà°Ç°­´º½º icon2
 
left
Àαâ°Ë»ö¾î
  Áö½Ä°Ë»ö   °Ë»ö
right

Á¦¸ñ °¡Àå È¿°ú ÁÁÀº Ç×±Õ¼º ¿Ü¿ëÁ¦ 2003-07-07 ¿ÀÀü 12:00
ÀÛ¼ºÀÚ Àü¼º¼ö Á¶È¸¼ö 5745   Ãßõ 1
Ä«Å×°í¸®

 

 

 

°¡Àå È¿°ú ÁÁÀº Ç×±Õ¼º ¿Ü¿ëÁ¦

 

 

 

 

 

 

3 ¼ººÐ º¹ÇÕÁ¦

 

 

ÇǺΰ¨¿°¿¡ »ç¿ëµÇ´Â ±¹¼Ò¿ë Ç×±ÕÁ¦Áß


¼¼ ¼ººÐ º¹ÇÕÁ¦°¡ ´Ü¿¬ ¿ì¼öÇÏ´Ù

 

Neomycin °ú

 

Bacitracin °ú

 

Polymixin B  º¹ÇÕÁ¦´Ù

 

 

ÀÌ´Â Àǻ縦 ´ë»óÀ¸·ÎÇÑ


ÃÖ½ÅÀÇ ¹ÌÁÖÁö¿ª º¸¼ö±³À°À»ÅëÇØ


¹ßÇ¥µÈ ³»¿ëÀÌ´Ù

 


 

 

Folliculitis(¸ð³¶¿°)    Impetigo(³ó°¡Áø)               Ecthyma(½ÉºÎ ³ó°¡Áø)
Erysipelas(´Üµ¶)      Lymphangitis(Àӯİü¿°)     Cellulitis(ºÀ¼ÒÁ÷¿°)

Furuncle(Á¾±â)         Carbuncles(¿©·¯ °÷ÀÇ Á¾±â)

 

 

 

 


 

¼¼°è ¾î´À ³ª¶ó³ª ¸¶Âù°¡Áö

 

 

 

 

 

 

 

¾Æ¿ï·¯

 

NeomycinÀ» ÇÔÀ¯ÇÑ 3Áß º¹ÇÕÁ¦°¡


Àü ¼¼°è ¾î´À ³ª¶ó¿¡¼­³ª


°¡Àå ¿ì¼öÇÑ ¿Ü¿ëÁ¦·Î »ç¿ëµÉ¼öÀÕÀ½À»


°­Á¶Çϰí ÀÖ´Ù

 

 

»Ó¸¸¾Æ´Ï¶ó


ÇǺΠ°ú¹Î¹ÝÀÀÀ» ÀÏÀ¸ÄÑ


Á¢Ã˼º ÇǺο°À» À¯¹ßÇÑ´ÙÇÏ¿©


Áö±Ý±îÁö °æ¿ø½Ã µÇ¾î ¿Â  NeomycinÀÌ


ÀüÇô ±×·¸Áö ¾Ê´Ù´Â »ç½Ç±îÁö ÀÔÁõÇÏ¿´´Ù

 

 


 

ÇǺΰ¨¿° ÁÖ¿ªÀº 4°¡Áö ±Õ

 

 

 ±×¶÷(+)±Õ

 ±×¶÷(-)±Õ

 

 

 

ÃÖ½ÅÀÇ ¼¼°èÀû Åë°è ÀÚ·á¿¡ÀÇÇϸé


ÇǺμ¼±Õ°¨¿°À» ÀÏÀ¸Å°´Â ÁÖ¿ªÀº 


¾î´À ³ª¶ó¸¦ ¸··ÐÇϰí


4°¡Áö ±Õ¿¡ ±¹ÇѵȴÙ


 

 

ÃÖ°í ºóµµÀÇ ÇǺΰ¨¿°±Õ Æ÷µµ±¸±Õ

 

 

 

±×¶÷¾ç¼º±Õ¿¡¼­´Â


Æ÷µµ»ó ±¸±Õ °ú ¿¬¼â»ó±¸±ÕÀ̰í

 

 


±×¶÷À½¼º ±Õ¿¡¼­´Â


´ëÀå±Õµî °ú ³ì³ó±ÕÀÌ´Ù

 

 

 ±×¶÷(-) ´ëÀå±Õ

 

 Enterococcus faecalis

 

 

 

 

 

±Õ°Ë»ç¸¦ ÇÏÁö ¾Ê°í »ç¿ëÇÒ ¶§

 

 

 

ÀÌ ³× °¡Áö ±ÕÀÌ ÀÏÀ¸Å°´Â


ÇǺΠ°¨¿°À» Ä¡·áÇϱâ À§ÇØ


±Õ°Ë»ç¸¦ ÇÏÁö ¾Ê°í


¿Ü¿ë¾àÀ» ¼±ÅÃÇÏ·Á¸é

 


 ³ó°¡Áø(Impetigo)

 


±×¶÷ ¾ç¼º±Õ°ú ±×¶÷À½¼º±ÕÀ»


¸ðµÎ Á¦°ÅÇÒ ¼ö ÀÖ´Â °ÍÀ̾î¾ß ÇÑ´Ù

 

 

 

Mupirocin

 

 

 

 

µû¶ó¼­ ±×¶÷¾ç¼º±Õ¿¡¸¸ µè´Â


MupirocinÀº ´ç¿¬ Á¦¿ÜµÇ¾ßÇÑ´Ù

 

 


Äû³ë·Ð°è Ç×±ÕÁ¦

 

 ³»¼º À¯¹ß °úÁ¤

 


¶ÇÇÑ


±¤¹üÀ§Ç×±ÕÁ¦Áß¿¡¼­µµ


Äû³ë·Ð°è Ç×±ÕÁ¦´Â 


³»¼ºÀÌ Àß À¯¹ßÇÑ´ÙÇÏ¿©


ºñ±³Æò°¡¿¡¼­ Á¦¿ÜµÇ¾ú´Ù

 

 

 


 

 

 

±¤¹üÀ§Çϸ鼭µµ 


¿Ü¿ëÁ¦·Î »ç¿ë½Ã


³»¼ºÀ» °¡Àå Àß ÀÏÀ¸Å°Áö ¾Ê´Â


Neomycin °ú


Bacitracin °ú


PolymixinÀ» ´ë»óÀ¸·Î ÇÏ¿©


ºñ±³ Æò°¡ÇÑ °á°ú´Â ´ÙÀ½°ú °°´Ù

 

 

³ó°¡Áø(Impetigo)

 

 

 

A

Neomycin

B

Bacitracin

C

Polymixin

A+B A+C B+C

A

+B+C

Æ÷µµ±¸±Õ 1 54 61 »ó½Â »ó°¡ »ó°¡ »ó½Â
Àå³»±¸±Õ 16 108 975 »ì°¡ »ó½Â »ó°¡ »ó½Â
´ëÀå±Õ 8 >6917 1 »ó°¡ »ó°¡ »ó°¡ »ó½Â
³ì³ó±Õ 32 >6917 8 »ó½Â »ó°¡ »ó½Â »ó½Â

 ¼ýÀÚ: MIC ³óµµ

      
Neomycin
Bacitracin

Polymixin-B

 

 

 

 

¾ÆÅäÇǼº ÇǺο° ÀÇ °¨¿°

 

 

 

 

 

¾ÆÅäÇǼº ÇǺο°ÀÌ ³­Ä¡È­µÇ´Â °ÍÀº


³»¼º Æ÷µµ±¸±ÕÀÌ °¨¿°µÇ±â ¶§¹®ÀÌ´Ù

 

 

 

 

 

3 ¼ººÐ º¹ÇÕÁ¦´Â MRSA ³»¼º Æ÷µµ±¸±Õ °ú


Mupirocin ³»¼ºÆ÷µµ±¸±Õ 25±ÕÁ¾¿¡´ëÇØ


MICº¯È­¾øÀÌ »ì±ÕÇÑ´Ù

 

 

 

 


Neomycin¿¡´ëÇÑ ¿ÀÇØ

 

NeomycinÀº Aminoglycoside°è Ç×±ÕÁ¦´Ù


±×¶÷¾ç¼º°ú ±×¶÷ À½¼º¿¡ ±¤¹üÀ§ÇÏ°Ô µè´Â Ç×±ÕÁ¦´Ù

 

 

 ½ÉºÎ³ó°¡Áø(Ecthyma)

 

 

 


±×·¯³ª °ú¹Î¹ÝÀÀ¿¡ÀÇÇÑ À̸¥¹Ù Á¢Ã˼º ÇǺο°À» ÀÏÀ¸Å²´Ù´Â


°ú°ÅÀÇ À߸øµÈ º¸°í·Î ÀÎÇØ


»ç¿ëÀ» °ÅÀÇ ±âÇÇÇØ¿Â  Ç×±ÕÁ¦´Ù

 

 

Á¢Ã˼º ÇǺο°

 

 

 

±×·¯³ª

 

2175¸í(18-25¼¼)À» ´ë»óÀ¸·ÎÇÑ ÀÓ»óÀ» ÅëÇØ


ÀüÇô »ç½Ç ¹«±ÙÀÓÀÌ ¹àÇôÁ³´Ù

 

 

Á¢Ã˼º¾Ù·¯Áö¹ÝÀÀ ºñ¾Ù·¯Áö¹ÝÀÀ

20% Neomycin

Skin Test

0.09% 0.9%

                            

 

¶ÇÇÑ ¼Ò¾Æ 653¸íÀ» ´ë»óÀ¸·ÎÇÑ ½ÇÇè¿¡¼­´Â Skintest¿¡¼­


98¸íÀÌ ¾ç¼ºÀ̾ú´Ù

 

±×·¯³ª À̵鿡°Ô Neomycin¿Ü¿ëÁ¦¸¦ »ç¿ëÇßÀ» ¶§ ´Ü 1¸í¸¸ÀÌ


Á¢Ã˼º ¾Ù·¯Áö ¹ÝÀÀÀ» ³ªÅ¸³»¾ú´Ù


À̿ܿ¡µµ ¸î °¡Áö ´ëÇü ÀÓ»ó ¸ðµÎ°¡ Á¢Ã˼º ¹ÝÀÀÀÌ °ÅÀÇ ¾øÀ½À»

³ªÅ¸³»°íÀÕ´Ù


 

 

 

 


¿¹¹æ¿ë Ç×±Õ ¿ä¹ý

 

ÇǺο¡ ¹Ù¸£´Â Ç×±Õ¼º ¿Ü¿ë¾àÀº


°¨¿° ¿¹¹æ¿ëÀ¸·Î °¡Àå ¸¹ÀÌ »ç¿ëµÈ´Ù

 

 

»óó°¡ ³ª°Å³ª ¼ö¼úÇÑÀÚ¸®¸¦

¿Ü°úÀûÀ¸·Î µå·¹½ÌÇÑÈÄ


±×´ë·Î ³ëÃâ½ÃÄѳõÀ¸¸é


µüÁö°¡ »ý±â¹Ç·Î


»õ ÇǺΰ¡ µ¸¾Æ³ª·Á¸é 3ÁÖ³ª °É¸°´Ù

 

 

 

 

 

±×·¯³ª


µå·¹½ÌÈÄ °¡Á¦ µîÀ¸·Î µ¤¾î³õÀ¸¸é


1ÁÖ¸¸ ÇǺΰ¡ Àç»ýÇÑ´Ù

 

 

ÇÏÁö¸¸


µ¤¾î ³õÀ¸¸é ½À±â°¡ Â÷¼­


º´±ÕÀÌ Áõ½ÄÇϸé


ÇǺΠ°¨¿°À» ÀÏÀ¸Å°±â½±»óÀÌ´Ù

 

 

¶§¹®¿¡ Ç×±Õ¼º ¿Ü¿ëÁ¦¸¦ ¹ß¸¥´Ù

 

 

 

 

 

 

ÇѱÕÁ¦¸¦ ¹Ù¸£¸é µ¤¾î³õ´Â


µüÁö°¡ »ý±â´Â °Íµµ ¸·À»¼öÀÕ´Ù


°¡Á¦·Î µ¤´Â °æ¿ìº¸´Ù


ÇǺÎÀÇ »ö»ó º¯È°±Û 38%ÀÌ»ó ¹æÁöÇØÁØ´Ù

 

 

 

Ãâ»ê¾Æ ÅÈÁÙ cutting

 

 

 

 

 

¾ËÄÚ¿Ã ¼Òµ¶Àº Àç°íµÇ¾ßÇÑ´Ù

 

ÇǺΠÀÚ¸¥ ÀÚ¸®³ª »óóÀÚ¸®¿¡


¾ËÄڿ÷Π¼Òµ¶ÇÏ´Â °ÍÀº À§ÇèÇÏ´Ù

 

ÇǺθ¦ ÀÚ±ØÇÏ°í »óó ȸº¹À» Áö¿¬½Ã۱⠶§¹®ÀÌ´Ù

 

 

 

[±Ù°Å]
The Role of Topical Antibiotics in Dermatologic Practice CME
Author: J.J. Leyden, MD Professor Emeritus, Dermatology,
University of Pennsylvania, Philadelphia; Professor of
Dermatology, University of Pennsylvania Hospital, Philadelphia;
June 25, 2003; Valid through June 25, 2004; for physicians and nurses.;
accredited by the Accreditation Council for Continuing Medical
Education (ACCME) to provide continuing medical education
for physicians; The American Medical Association has determined
that non-US licensed physicians who participate in this CME
activity are eligible for AMA PRA category 1 credit.

 Medscape's CME/CE activity.

 


 



 
 
¹øÈ£Á¦¸ñÀÛ¼ºÀÚ Ãßõ µî·ÏÀÏ Á¶È¸¼ö
ÀÌÀü Ç×±Õ¿ä¹ý Ȳ±ÝÀ² - Ç×±Õ¿ä¹ý Àü¹Ý¿¡ Àû¿ëµÇ´Â 16°¡Áö ±âº» Áöħ Àü¼º¼ö °Ô½ºÆ® 4 2002-01-23 5948
About us |  Contact us |  FAQ |  Service ¾È³» |  ±¤°í ¹× Á¦È޾ȳ» |  °³ÀÎÁ¤º¸Ãë±Þ¹æÄ¨ |  SiteMap
copy copy